A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

NCT02139943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

352

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Canagliflozin 100 mg
DRUG: Canagliflozin 300 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC